Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.

Frontiers in immunology - 1 Jan 2020

Lin Anqi, Zhang Jian, Luo Peng

Abstract excerpt

Colorectal cancer (CRC) patients, especially those with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune checkpoint inhibitors (ICIs) is significantly higher than that of patients with microsatellite-stable (MSS)/microsatellite instability-low (MSI-L) tumors, have derived clinical benefits from immunotherapy. Most studies have not systematically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Management
Share to Disease Susceptibility
Share to DNA Damage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunomodulation

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32903444
DOI: 10.3389/fimmu.2020.02039
PMCID: PMC7435056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.PMID 32903444Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.Semantic proximity Read ↗

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancerSemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancerSemantic proximity Read ↗

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatmentSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read ↗

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal CancerSemantic proximity Read ↗

A subset of patients with MSS/MSI‑low‑colorectal cancer showed increased CD8(+) TILs together with up‑regulated IFN‑γSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.